SI1871347T1 - Farmacevtski sestavek - Google Patents

Farmacevtski sestavek

Info

Publication number: SI1871347T1
Authority: SI; Slovenia
Prior art keywords: pharmaceutical composition; pharmaceutical; composition
Prior art date: 2005-04-19

Application number

SI200632109A

Other languages

English (en)

Inventor

Barry Howard GlaxoSmithKline Corp. Int. CARTER

Dwayne A. GlaxoSmithKline Corp. Int. CAMPBELL

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-04-19

Filing date

2006-04-18

Publication date

2016-11-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37115487&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI1871347(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2006-04-18 Application filed by Novartis Ag filed Critical Novartis Ag

2016-11-30 Publication of SI1871347T1 publication Critical patent/SI1871347T1/sl

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

SI200632109A 2005-04-19 2006-04-18 Farmacevtski sestavek SI1871347T1 (sl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US67280505P	2005-04-19	2005-04-19
EP06750475.3A EP1871347B1 (en)	2005-04-19	2006-04-18	Pharmaceutical composition
PCT/US2006/014447 WO2006113649A1 (en)	2005-04-19	2006-04-18	Pharmaceutical composition

Publications (1)

Publication Number	Publication Date
SI1871347T1 true SI1871347T1 (sl)	2016-11-30

Family

ID=37115487

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SI200632109A SI1871347T1 (sl)	2005-04-19	2006-04-18	Farmacevtski sestavek

Country Status (28)

Country	Link
US (3)	US8821927B2 (sl)
EP (1)	EP1871347B1 (sl)
JP (1)	JP5202302B2 (sl)
KR (1)	KR101356748B1 (sl)
CN (1)	CN101203211B (sl)
AR (1)	AR054252A1 (sl)
AU (1)	AU2006236423B2 (sl)
BR (1)	BRPI0609962B1 (sl)
CA (1)	CA2606207C (sl)
CY (1)	CY1118179T1 (sl)
DK (1)	DK1871347T3 (sl)
EA (1)	EA200702253A1 (sl)
ES (1)	ES2601503T3 (sl)
HR (1)	HRP20161429T1 (sl)
HU (1)	HUE030982T2 (sl)
IL (1)	IL186336A0 (sl)
LT (1)	LT1871347T (sl)
MA (1)	MA29404B1 (sl)
MX (1)	MX2007013089A (sl)
NO (1)	NO20075111L (sl)
NZ (1)	NZ562223A (sl)
PE (1)	PE20061430A1 (sl)
PL (1)	PL1871347T3 (sl)
PT (1)	PT1871347T (sl)
SI (1)	SI1871347T1 (sl)
TW (1)	TW200716204A (sl)
WO (1)	WO2006113649A1 (sl)
ZA (1)	ZA200708705B (sl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1871347B1 (en) *	2005-04-19	2016-08-03	Novartis AG	Pharmaceutical composition
WO2009137714A2 (en) *	2008-05-07	2009-11-12	Teva Pharmaceutical Industries Ltd.	Forms of lapatinib ditosylate and processes for preparation thereof
EP2158912A1 (en)	2008-08-25	2010-03-03	Ratiopharm GmbH	Pharmaceutical composition comprising N-[3-chhloro-4-[3-fluorophenyl)methoxy)phenyl]6-[5[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine
EP2158913A1 (en)	2008-08-25	2010-03-03	Ratiopharm GmbH	Pharmaceutical composition comprising N-[3-chhloro-4-[(3-fluorophenyl)methoxy]phenyl]6-(5[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine
WO2010099150A1 (en) *	2009-02-24	2010-09-02	Smithkline Beecham (Cork) Limited	Pharmaceutical tablet and process
US20120245351A1 (en) *	2009-09-29	2012-09-27	Natco Pharma Limited	Process for the preparation of lapatinib and its pharmaceutically acceptable salts
JP2013526578A (ja)	2010-05-21	2013-06-24	グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー	組合せ
WO2011146712A1 (en)	2010-05-21	2011-11-24	Glaxosmithkline Llc	Combination
EA030145B1 (ru)	2010-08-03	2018-06-29	Велисепт Терапьютикс, Инк.	Комбинации агонистов бета-3-адренергических рецепторов и антагонистов мускариновых рецепторов для лечения гиперактивности мочевого пузыря
US9907767B2 (en)	2010-08-03	2018-03-06	Velicept Therapeutics, Inc.	Pharmaceutical compositions and the treatment of overactive bladder
WO2014128107A1 (en)	2013-02-19	2014-08-28	Hexal Ag	Pharmaceutical composition comprising n-[3-chloro-4-(3-fluorobenzyloxy)phenyl]-6-[5({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]quinazolin-4-amine or a pharmaceutically acceptable salt, solvate or solvated salt thereof
WO2014170910A1 (en)	2013-04-04	2014-10-23	Natco Pharma Limited	Process for the preparation of lapatinib
US9636340B2 (en)	2013-11-12	2017-05-02	Ayyappan K. Rajasekaran	Kinase inhibitors
KR20170086659A (ko)	2014-12-03	2017-07-26	벨리셉트 테라퓨틱스, 인크.	하부 요로 증상을 위한 변형 방출형 솔라베그론을 이용한 조성물 및 방법
CN106389373B (zh) *	2015-07-29	2019-07-02	四川科伦药物研究院有限公司	一种二甲苯磺酸拉帕替尼片剂及其制备方法
CN106511289A (zh) *	2015-09-10	2017-03-22	湖北生物医药产业技术研究院有限公司	甲苯磺酸拉帕替尼片剂及其制备方法
FI3365321T3 (fi)	2015-10-23	2024-01-02	B3Ar Therapeutics Inc	Solabegron-Zwitterioni ja sen käyttöjä

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5506248A (en) *	1993-08-02	1996-04-09	Bristol-Myers Squibb Company	Pharmaceutical compositions having good dissolution properties
GB9508538D0 (en)	1995-04-27	1995-06-14	Zeneca Ltd	Quinazoline derivatives
US5760041A (en)	1996-02-05	1998-06-02	American Cyanamid Company	4-aminoquinazoline EGFR Inhibitors
AU738628B2 (en)	1997-04-25	2001-09-20	Janssen Pharmaceutica N.V.	Farnesyltransferase inhibiting quinazolinones
TW436485B (en)	1997-08-01	2001-05-28	American Cyanamid Co	Substituted quinazoline derivatives
GB9800569D0 (en)	1998-01-12	1998-03-11	Glaxo Group Ltd	Heterocyclic compounds
IL153111A0 (en) *	2000-06-30	2003-06-24	Glaxo Group Ltd	Quinazoline ditosylate salt compounds
ES2236481T3 (es)	2001-01-16	2005-07-16	Glaxo Group Limited	Combinacion farmaceutica que contiene una 4-quinazolinamina y paclitaxel, carboplatino o vinorelbina para el tratamiento de cancer.
JP2005534623A (ja)	2002-04-08	2005-11-17	スミスクラインビーチャムコーポレーション	Ｅｒｂファミリーの阻害剤並びにｒａｆ及び／又はｒａｓ阻害剤を投与することを含む癌の治療法
AU2003235470A1 (en) *	2002-06-19	2004-01-06	Smithkline Beecham Corporation	Predictive markers in cancer therapy
EP1871347B1 (en) *	2005-04-19	2016-08-03	Novartis AG	Pharmaceutical composition

2006
- 2006-04-18 EP EP06750475.3A patent/EP1871347B1/en active Active
- 2006-04-18 EA EA200702253A patent/EA200702253A1/ru unknown
- 2006-04-18 LT LTEP06750475.3T patent/LT1871347T/lt unknown
- 2006-04-18 CN CN2006800219417A patent/CN101203211B/zh active Active
- 2006-04-18 US US11/911,843 patent/US8821927B2/en active Active
- 2006-04-18 CA CA2606207A patent/CA2606207C/en active Active
- 2006-04-18 AU AU2006236423A patent/AU2006236423B2/en not_active Revoked
- 2006-04-18 HU HUE06750475A patent/HUE030982T2/en unknown
- 2006-04-18 MX MX2007013089A patent/MX2007013089A/es active IP Right Grant
- 2006-04-18 TW TW095113811A patent/TW200716204A/zh unknown
- 2006-04-18 PL PL06750475T patent/PL1871347T3/pl unknown
- 2006-04-18 DK DK06750475.3T patent/DK1871347T3/en active
- 2006-04-18 KR KR1020077026740A patent/KR101356748B1/ko active IP Right Grant
- 2006-04-18 BR BRPI0609962-9A patent/BRPI0609962B1/pt active IP Right Grant
- 2006-04-18 ES ES06750475.3T patent/ES2601503T3/es active Active
- 2006-04-18 PE PE2006000406A patent/PE20061430A1/es not_active Application Discontinuation
- 2006-04-18 WO PCT/US2006/014447 patent/WO2006113649A1/en active Application Filing
- 2006-04-18 NZ NZ562223A patent/NZ562223A/en not_active IP Right Cessation
- 2006-04-18 PT PT67504753T patent/PT1871347T/pt unknown
- 2006-04-18 SI SI200632109A patent/SI1871347T1/sl unknown
- 2006-04-18 AR AR20060101526A patent/AR054252A1/es not_active Application Discontinuation
- 2006-04-18 JP JP2008507783A patent/JP5202302B2/ja active Active
2007
- 2007-10-07 IL IL186336A patent/IL186336A0/en unknown
- 2007-10-09 NO NO20075111A patent/NO20075111L/no not_active Application Discontinuation
- 2007-10-11 ZA ZA200708705A patent/ZA200708705B/xx unknown
- 2007-10-25 MA MA30318A patent/MA29404B1/fr unknown
2014
- 2014-07-28 US US14/444,637 patent/US20140335177A1/en not_active Abandoned
2016
- 2016-01-29 US US15/009,927 patent/US20160143909A1/en not_active Abandoned
- 2016-11-02 HR HRP20161429TT patent/HRP20161429T1/hr unknown
- 2016-11-03 CY CY20161101115T patent/CY1118179T1/el unknown

Also Published As

Publication number	Publication date
AU2006236423B2 (en)	2009-12-10
NO20075111L (no)	2007-11-16
CY1118179T1 (el)	2017-06-28
MA29404B1 (fr)	2008-04-01
MX2007013089A (es)	2008-01-14
ES2601503T3 (es)	2017-02-15
PL1871347T3 (pl)	2017-04-28
US20080206330A1 (en)	2008-08-28
NZ562223A (en)	2010-01-29
IL186336A0 (en)	2008-01-20
EP1871347A4 (en)	2012-10-31
AR054252A1 (es)	2007-06-13
EP1871347B1 (en)	2016-08-03
CN101203211B (zh)	2012-08-08
PT1871347T (pt)	2016-11-10
LT1871347T (lt)	2016-11-10
JP2008536931A (ja)	2008-09-11
HRP20161429T1 (hr)	2016-12-16
KR20080005557A (ko)	2008-01-14
WO2006113649A1 (en)	2006-10-26
ZA200708705B (en)	2009-12-30
BRPI0609962A2 (pt)	2011-10-11
TW200716204A (en)	2007-05-01
EP1871347A1 (en)	2008-01-02
CN101203211A (zh)	2008-06-18
HUE030982T2 (en)	2017-06-28
CA2606207A1 (en)	2006-10-26
EA200702253A1 (ru)	2008-04-28
KR101356748B1 (ko)	2014-02-06
PE20061430A1 (es)	2007-01-25
CA2606207C (en)	2014-11-18
US20160143909A1 (en)	2016-05-26
US20140335177A1 (en)	2014-11-13
AU2006236423A1 (en)	2006-10-26
US8821927B2 (en)	2014-09-02
JP5202302B2 (ja)	2013-06-05
BRPI0609962B1 (pt)	2022-01-18
DK1871347T3 (en)	2016-11-28

Publication	Publication Date	Title
HK1244267A1 (zh)	2018-08-03	包含(r)-n-甲基納曲酮的藥物組合物
GB0513692D0 (en)	2005-08-10	Novel pharmaceutical compositions
IL177480A0 (en)	2006-12-10	Pharmaceutical composition
ZA200708705B (en)	2009-12-30	Pharmaceutical composition
AP2008004533A0 (en)	2008-08-31	Pharmaceutical combination
IL188352A0 (en)	2008-04-13	Pharmaceutical compositions
IL187748A0 (en)	2008-04-13	Pharmaceutical compositions containing misoprostal
ZA200804103B (en)	2009-10-28	Pharmaceutical compositions
EP1937255A4 (en)	2013-06-26	PHARMACEUTICAL COMPOSITION
EP1862184A4 (en)	2012-12-19	PHARMACEUTICAL COMPOSITION
GB0522045D0 (en)	2005-12-07	Pharmaceutical compositions
IL192091A0 (en)	2008-12-29	Pharmaceutical compositions
EP2124959A4 (en)	2011-09-14	PHARMACEUTICAL COMPOSITION
HU0401177D0 (en)	2004-08-30	Pharmaceutical composition
GB2411355B (en)	2006-02-22	Pharmaceutical composition
ZA200804666B (en)	2010-01-27	Pharmaceutical combination
EP1845944A4 (en)	2011-07-27	PHARMACEUTICAL COMPOSITIONS
ZA200701932B (en)	2008-08-27	Pharmaceutical composition
GB0425255D0 (en)	2004-12-15	Pharmaceutical composition
ZA200701931B (en)	2008-10-29	Pharmaceutical composition
GB0512246D0 (en)	2005-07-27	Novel pharmaceutical
ZA200803566B (en)	2009-10-28	Pharmaceutical compositions
GB0514259D0 (en)	2005-08-17	Pharmaceutical compositions
HUP0401176A2 (en)	2007-09-28	Pharmaceutical composition having prpkinetic effect
GB0402799D0 (en)	2004-03-10	Pharmaceutical composition